ABSTRACT
Objective To discuss the blockage reasons and countermeasures of temporary catheter in central venous including femoral vein and internal jugular vein for hemodialysis patients.Methods The reasons of blockage of temporary catheter in central venous among 60 hemodialysis patients from January 2014 to September 2015 in Hemodialysis Room of the First People's Hospital of Longquanyi district of Chengdu were reviewed.There were 32 cases in femoral vein and 28 cases in the right internal jugular vein.The incidence of blockage of the two temporary catheter in the first two weeks,the incidence of blockage caused by mechanical factors and blood clots or fibrous sheath and the incidence of blockage which needed to change the catheter in the two groups patients within the first two months were analyzed.Results The first rate of defective function in the first two weeks of femoral vein group was 53.13％(17/32),and 7.14％(2/28) of the right internal jugular vein group,there were significant difference between the two groups (x2=13.061,P＜0.001).The incidence of catheter blockage due to mechanical factors of femoral vein group was 96.88％ (31/32),and 53.57％ (15/28) of the right internal jugular vein,there were significant difference between the two groups (x2 =15.654,P＜0.001).The incidence of blockage caused by blood clots or fibrous sheath and the incidence of blockage which needed to change the catheter in the first two months were no significant differences between the two groups(P=0.061,0.096).Conclusion The cases of temporary catheter in femoral vein have blockage earlier,and they have a higher risk of catheter jam than the cases of temporary catheter in right internal jugular vein.
ABSTRACT
This is a research project aimed at investigating the clinical efficiency of W-F168-B, a dialyzer reprocessing machine made by Weilisheng Biological Material Company in Chengdu, evaluating its effects on total cell volume (TCV) and dialysis sufficiency, and assessing its disinfection efficacy. All subjects were randomly divided into two groups, whose dialyzers were reprocessed by W-F168-B (made in Chengdu) and RENATRON II (made by MINNTECH Company in the United States) respectively. We detected TCV of the dialyzer before and after reusing and calculated their diversity. We also calculated all subjects' Kt/V. The values of TCV diversities of two groups were 5.5 +/- 4.15 (experimental group) and 4.5 +/- 2.56 (control group) respectively, P > 0.05. The levels of Kt/V of experimental group and control group were 1.25 +/- 0.26 and 1.24 +/- 0.19, P > 0.05. T-test showed that there was no statistically significance difference between the two groups. The result of every hemoculture is negative. In conclusion, these two dialyzer reprocessing machines are similar in the effect of the dialyzer's performance and the subject's dialysis sufficiency. The reused dialyzers reprocessed by these two machines are safe for use.
Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Equipment Contamination , Equipment Reuse , Evaluation Studies as Topic , Renal Dialysis , Safety , Urea , BloodABSTRACT
Objective To investigate antithrombotic and antiplatelet effects of Dragon's Blood,?-cyclodextrin inclusion of Dragon's Blood.Methods The methods of injection of adenosin diphosphate(ADP) into mouse tail vein,electrically stimulated arterial thrombosis in rats were used to evaluate the anti-thrombotic effects of Dragon's Blood and?-cyclodextrin inclusion of Dragon's Blood,respectively.Platelet aggregation(PRP or washed platelets) was tested according to Born's method.Results ?CYDB significantly protected against thrombosis caused by ADP on mice,and electrical stimulation on rats.In vitro?-cyclodextrin inclusion of Dragon's Blood inhibited AA,ADP,PAF-induced platelet aggregation.Conclusions The results suggest that compared with Dragon's Blood,?-cyclodextrin inclusion of Dragon's Blood has more potent anti-thrombotic effects on the thrombotic models,its mechanisms may be closely related to the inhibition of anti-platelet aggregation.?-cyclodextrin inclusion of Dragon's Blood can improve the bioavailability of Dragon's Blood.
ABSTRACT
The authors report 105 cases of neurologic manifestation ia 822 patients with pulmonary carcinoma, with an incidence of neurological complication of 19.5%. The neurologic manifestations were the first symptom in 64 cases (61%), which showed orderly as headache, hemi-plegia, seizure, paraplegia, mental sympioms, backache, vertigo, sciatica, facial palsy, etc. In these 105 cases there were 93 suffered metastasis, which involved cerebrum, spinal cord, meninges, cerebellum etc. Twelve patients were nonmetastatic, among whom, carcinomaious encephalopathy, myopathy, dermtomyositis etc were observed